The Role of Hippocampal Interneuron Migration in Neurodevelopmental Disorders: A Systematic Review.

HippocampusSep 1, 2026
Clinical ResearchNeurologyPsychiatryOpen access

M A C Till, H M O Reid, I Murphy et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined the role of aberrant hippocampal interneuron migration in neurodevelopmental disorders, analyzing 29 studies. It found a clear association between deficits in interneuron migration and the manifestation of these disorders, highlighting subtype-specific differences. The review adhered to PRISMA guidelines and synthesized findings from a broad literature search.

Key findings

  • A total of 1459 papers were screened, resulting in 29 articles meeting inclusion criteria.
  • There is evidence of interneuron involvement in various neurodevelopmental conditions.
  • Distinct regional and subtype-specific differences in interneuron migration were identified.
  • The review noted a significant lack of consideration for sex differences in the research.

Why it matters

Understanding the role of interneuron migration in neurodevelopmental disorders can inform future research directions and therapeutic strategies. Identifying specific deficits may lead to targeted interventions and improved outcomes for affected individuals.

Source

PubMed · PMID 42608292Free full text on PubMed Central

Published in Hippocampus. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.